Mineralys Therapeutics Current Cash

The latest current cash for MLYS is $110M as of March 2026. That compares with $170M in the prior-year period — down 31.7% year over year. Investors often review this figure alongside Mineralys Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MLYS's current cash moved from $170M to $110M — a 31.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mineralys Therapeutics's operating scale or balance-sheet position.

A current cash figure of $110M for MLYS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MLYS's current cash ($110M), review year-over-year change from $170M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.